Hepatitis B Virus Core Antigen (HBcAg) anticorps (Biotin)

N° du produit ABIN722993

Détail du produit

Antigène: Hepatitis B Virus Core Antigen (HBcAg)

Reactivité: Hepatitis B Virus (HBV), Virus

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Biotin

Application: ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Réactivité croisée: Virus

Réactivité croisée (Details): Hepatitis B Virus

Purification: Purified by Protein G.

Immunogène: Recombinant Hepatitis B Core Antigen (rHBcAg)

Clone: 1H8

Isotype: IgG

Information d'application

Indications d'application: IHC-P 1:200-400

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détail du antigène

Antigène: Hepatitis B Virus Core Antigen (HBcAg)

Autre désignation: HBcAg (HBcAg Produits)

Synonymes: anticorps precore; HBe antigen; PreC; HBeAg; precore protein; external core antigen; HBeAg; p25, anticorps C

Classe de substances: Viral Protein

Sujet:

Synonyms: C, Capsid protein, Core and e antigen, Core antigen, Core antigen, Core protein, HBc, HBcAg, HBVgp4, Hepatitis B Virus core antigen, p21.5, precore/core protein, CAPSD_HBVA3.

Background: Hepatitis B Virus Core Antigen (HBcAg) is part of the infectious virion containing an inner "core particle" enclosing the viral genome. The icosahedral core particle contains 180 or 240 copies of the core protein. HBcAg is one of the three major clinical antigens of hepatitis B virus but disappears early in the course of infection.The hepatitis B virus core antigen (HBcAg) is a highly immunogenic subviral particle and functions as both a T-cell-dependent and a T-cell-independent antigen. Therefore, HBcAg may be a promising candidate target for therapeutic vaccine control of chronic HBV infection.